Prospective, Randomized Study Showed Durability of Clinical Outcomes in the TIF group and Improved Control of GERD symptoms in the Crossover Group SAN MATEO, Calif. (Oct. 8, 2014)–EndoGastric Solutions® (EGS), a leader in endoluminal reconstructive treatment for...
TIF procedure patients experienced similar reduction in reflux symptom resolution with significantly reduced operative times compared to Nissen or Toupet fundoplication techniques SAN MATEO, Calif. (Sept 3, 2014)–EndoGastric Solutions® (EGS), a leader in endoluminal...
Quality-of-Life Survey Scores on Medications and Presence of Esophagitis Appear to Be Best Correlated Predictors of Success SAN MATEO, Calif. (June 9, 2014)–EndoGastric Solutions® (EGS), a leader in endoluminal reconstructive treatment for gastroesophageal reflux...
Financing to Support Clinical Publications, Reimbursement Initiatives and Research and Development SAN MATEO, Calif. (May 6, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced...
